SCHEMBL22255018

SCHEMBL22255018

CSc1cc(Cl)c2nc(C)sc2c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 5/20 0.37
RAB9A P51151 4/20 0.37
MAPT P10636 3/20 0.37
NPC1 O15118 3/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
TP53 P04637 1/20 0.37
PKM P14618 1/20 0.37
ALOX15 P16050 2/20 0.36
ATM Q13315 1/20 0.36
GAA P10253 1/20 0.35
TSHR P16473 1/20 0.34
HSD11B1 P28845 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
F2RL3 Q96RI0 1/20 0.31
DHFR P00374 1/20 0.30
TYMS P04818 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20666434 0.79 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2RAB9ANPC1HPGD
SCHEMBL10272524 0.78 HSD17B10 (0.43) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL8334374 0.78 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL8330380 0.75 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL30626905 0.75 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL24603481 0.75 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL21098344 0.75 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL20049459 0.74 CHRNB2 (0.35) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL20667373 0.72 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1
SCHEMBL30626907 0.71 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2RAB9AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119367-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2022-04-21 US disclosed
US-20200231570-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2020-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200231570-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS ADORA2A, ADORA3, ADORA1 ALDH1A1 2100/4885SMN1; SMN2 4476/4885RAB9A 2816/4885
US-20220119367-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS ADORA2A, ADORA3, ADORA1 ALDH1A1 2100/4885SMN1; SMN2 4476/4885RAB9A 2816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.